GnRH receptor mutations have recently been identified in a small number of familial cases of nonanosmic hypogonadotropic hypogonadism. In the present report we studied a kindred in which two sisters with primary amenorrhea were affected with GnRH deficiency due to a compound heterozygote mutation (Gln 106 Arg, Arg 262 Gln) and performed extensive phenotyping studies.
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Baseline patterns of gonadotropin secretion and gonadotropin responsiveness to exogenous pulsatile GnRH were examined in the proband. Low amplitude pulses of both LH and free ␣-subunit (FAS) were detected during 24 h of every 10 min blood sampling. The proband then received exogenous pulsatile GnRH iv for ovulation induction, and daily blood samples for gonadotropins and sex steroids were monitored. At the conventional GnRH replacement dose for women with hypogonadotropic hypogonadism (75 ng/kg), no follicular development occurred. At a GnRH dose of 100 ng/kg, the level and pattern of gonadotropin secretion more closely mimicked the follicular phase of normal women; a single dominant follicle was recruited, and an endogenous LH surge was elicited. However, the luteal phase was inadequate, as assessed by progesterone levels. At a GnRH dose of 250 ng/kg, the gonadotropin and sex steroid dynamics reproduced those of normal ovulatory women in both the follicular and luteal phases, and the proband conceived. The FAS responses to both conventional and high dose GnRH were within the normal range.
The following conclusions were made: 1) Increased doses of GnRH may be used effectively for ovulation induction in some patients with GnRH receptor mutations. 2) Higher doses of GnRH are required for normal luteal phase dynamics than for normal follicular phase function. 3) Hypersecretion of FAS in response to exogenous GnRH, which is a feature of congenital hypogonadotropic hypogonadism, was not seen in this patient with a GnRH receptor mutation. I DIOPATHIC hypogonadotropic hypogonadism (IHH) commonly presents as pubertal delay and low sex steroid levels in the setting of low/normal gonadotropin levels in the absence of a systemic and/or anatomical cause. Although the gene for X-linked Kallmann syndrome [hypogonadotropic hypogonadism (HH) plus anosmia] was identified in the early 1990s (1, 2) , genes for the nonanosmic forms of HH have remained elusive. Recently, patients have been described with either homozygous or compound heterozygous mutations in the GnRH receptor (3) (4) (5) (6) (7) , with clinical phenotypes varying from partial to complete HH.
Recent reports have demonstrated resistance of hypogonadotropic patients with GnRH receptor mutations to either single GnRH injections (6) or exogenous pulsatile GnRH (5-7). However, as some patients with GnRH receptor mutations have presented with partial hypogonadism, suggesting some, albeit limited, responsiveness to endogenous GnRH, we hypothesized that a subset of such patients might demonstrate responsiveness to exogenous GnRH and thus be candidates for GnRH therapy with appropriate dose adjustments. This report describes the successful use of pulsatile GnRH for ovulation induction and conception in a female patient with a compound heterozygous GnRH receptor mutation. The incremental range of GnRH doses employed demonstrates the variable sensitivity of different stages of the menstrual cycle to GnRH dose. The lack of free ␣-subunit (FAS) hyperresponsiveness to GnRH replacement distinguishes this patient from others with HH.
Subjects and Methods

Case history
The proband (II:1) presented with primary amenorrhea (Fig. 1) . During adolescence, she had a small amount of pubic and axillary hair, but no breast development. She received oral estrogens for approximately 1.5 yr, but discontinued this medication as a college freshman. She was subsequently given two courses of Provera without estrogen pretreatment, one of which was followed by a withdrawal bleed. She presented to the Reproductive Endocrine Associates of Massachusetts General Hospital at age 25 yr for a second opinion of her amenorrhea. Her family history was notable for a younger sister who had also failed to menstruate spontaneously. Physical examination was notable for eunochoid habitus, small breasts, and normal external genitalia. Baseline LH and FSH levels were 0.3 and 0.5 IU/L, respectively. PRL and estradiol levels were 1.8 ng/mL and less than 20 pg/mL, respectively. In response to a single bolus of 100 g GnRH, iv, gonadotropin responses were markedly diminished, with a peak LH level of 1.3 IU/L at 30 min and a peak FSH level of 1.6 IU/L at 120 min. GH and cortisol responses to insulininduced hypoglycemia were normal. Brain imaging was normal, and the karyotype was 46,XX.
The following clinical studies were approved by the Subcommittee on Human Studies of Massachusetts General Hospital. After providing written informed consent, the proband was admitted to the General Clinical Research Center. Frequent blood sampling was performed ev-ery 10 min for 12 h for measurements of LH and FAS. After this baseline study, the proband underwent a number of cycles of ovulation induction using exogenous pulsatile GnRH therapy. Initially, a dose of 75 ng/kg, iv, was employed, as this dose has been previously shown to recreate most closely the normal physiology of an ovulatory cycle in a large series of women with primary and secondary HH (8) . When no ovulatory response was observed, the dose was increased to 100 ng/kg for three additional cycles. The dose was then subsequently raised to 250 ng/kg, and eight more cycles were performed. The frequency of GnRH administration was adjusted during each cycle to mimic the frequency changes in endogenous LH secretion that occur during a normal menstrual cycle (9) . A blood sample was obtained each day during treatment for LH, FSH, estradiol (E 2 ), and progesterone (P 4 ) determinations 45 min after a GnRH dose. In two cycles (75 ng/kg and the fourth cycle at 250 ng/kg), FAS was also measured in daily samples.
The patient conceived three times on pulsatile GnRH (250 ng/kg), but suffered recurrent pregnancy loss between 7-11 weeks gestation. She then underwent exogenous gonadotropin therapy, where she conceived again, but suffered two additional pregnancy losses. An embryo/trophoblast toxic factor was identified through an embryotoxic factorlymphocyte assay (10) . Her sister was treated with exogenous gonadotropins and bore three children: one twin pregnancy and one singleton.
Normal controls
One hundred and nine women between the ages of 18 -40 yr with regular cycles (25-35 days) had gonadotropins and sex steroids measured daily during a complete ovulatory cycle to define the normal ranges for these hormones (9, (11) (12) (13) . In addition, FAS was measured in a subset of 24 subjects (14) . Samples were drawn at the same time of day. All subjects were euthyroid, normoprolactinemic, of normal body weight, and taking no medications. All had evidence for ovulation in a cycle preceding their study cycle, as assessed by midluteal phase P 4 levels and/or basal body temperature charts.
Congenital IHH
The patient's FAS response to pulsatile GnRH was compared to that of 11 women with either IHH (n ϭ 5) or Kallmann syndrome (n ϭ 6) as previously described (14) . The latter group were defined by the following criteria: 1) absence of spontaneous puberty by age 18 yr; 2) primary amenorrhea; 3) absence of pulsatile gonadotropin secretion during 12-24 h of frequent (every 10 min) blood sampling; 4) normal basal and stimulated levels of TSH, PRL, GH, and cortisol on baseline and stimulated testing; and 5) no evidence of a mass lesion on brain imaging of the hypothalamic-pituitary region. After the baseline frequent gonadotropin sampling study confirmed the absence of pulsatile LH secretion, patients underwent ovulation induction using pulsatile GnRH at 75 or 100 ng/kg, iv. The frequency of GnRH administration was adjusted to mimic the frequency changes that occur during a normal menstrual cycle. A blood sample was obtained each day of the cycle, approximately 45 min after a GnRH pulse, for LH, FSH, E 2 , P 4 , and FAS (14) . Samples were drawn at the same time of day.
Assays
Serum LH and FSH concentrations were determined by immunoassays calibrated against the Second International Reference Preparation of human menopausal gonadotropin (WHO 71/223) (13, 15, 16) , with a minimal detectable dose of 0.8 IU (human menopausal gonadotropin, WHO 71/223)/L. Inter-and intraassay coefficients of variation were less than 10%. FAS was measured by a monoclonal antibody RIA, using a highly purified ␣-subunit of hCG as the standard (17, 18) .
Data analysis
Pulsatile hormone secretion was assessed using the modified version of the Santen and Bardin method as previously described (9, 19) . Levels of LH, FSH, E 2 , and P 4 during each cycle were analyzed in relation to the day of ovulation, as previously defined (9). The integrated P 4 level across the luteal phase (P 4 sum ) was calculated by summing the values between day Ϫ2 in relation to the day of ovulation and the day before the following menses. Conception cycles were excluded from this analysis. Hormone levels between the proband and normal women were compared using unpaired t tests. To compare FAS levels between the proband and IHH women, serum levels of FAS were analyzed in relation to the first 7 days of GnRH administration. Values are expressed as the mean Ϯ sem unless otherwise specified, and P Ͻ 0.05 was accepted as significant.
DNA extraction and sequencing
After providing informed consent, whole blood samples were donated by individuals I:1, I:2, II:1, II:2, and II:3, and DNA was extracted. Exons of the GnRH receptor were amplified by PCR using sets of primers reported previously (3) . Amplified products were sequenced in both the forward and reverse directions using the AmpliTaq Dye Terminator Cycle Sequencing kit and an ABI PRISM 377 DNA sequencer (PerkinElmer Corp., Foster City, CA). 
Results
DNA sequencing
Direct sequencing revealed two heterozygotic mutations in the proband as indicated in Fig. 2, A and B. In Exon 1, a guanine was substituted for an adenine at position 317, yielding a Gln 106 Arg mutation in the first extracellular loop ( Fig.  2A) . In exon 3, an adenine was substituted for a guanine at position 785, yielding an Arg 262 Gln mutation in the third intracellular loop (Fig. 2B) . The proband's sister was found to have identical mutations; the proband's brother had none. Each parent was found to be heterozygous, indicating that the patient had inherited germline mutations.
Baseline frequent blood sampling
Baseline LH and FAS profiles from the proband (II:1) are depicted in Fig. 3 . Five LH pulses and four FAS pulses of low amplitude were identified. Interestingly, a one to one concordance between LH and FAS pulses was not observed. The mean LH level was 2.0 Ϯ 0.1 mIU/mL, and the mean FAS level was 122.2 Ϯ 1.8 ng/L. The mean LH and FAS pulse amplitudes were 1.2 Ϯ 0.1 and 43.0 Ϯ 4.6, respectively.
Ovulation induction using pulsatile GnRH
Ovulation induction cycles using sequentially increasing doses of GnRH (75, 100, and 250 ng/kg) are depicted in Fig.  4 , A-C. Levels of gonadotropins and sex steroids are superimposed upon the normative ranges for these hormones as determined in 109 normally cycling women. Figure 4A depicts the first and only cycle using exogenous pulsatile GnRH at a dose of 75 ng/kg. There was no evidence of follicular development, as assessed by either ultrasound or serum E 2 levels, and an endogenous LH surge did not occur. Mean LH and FSH levels over the 27 days of therapy were 12.9 Ϯ 1.2 and 15.2 Ϯ 0.5 IU/L, respectively. Mean E 2 and P 4 levels were 50.0 Ϯ 2.7 pg/mL and 0.5 Ϯ 0.0 ng/mL, respectively. The dose of GnRH was then increased to 100 ng/kg, and three additional cycles were performed (Fig. 4B) . In contrast to 75 ng/kg, at this higher dose of pulsatile GnRH, a single dominant follicle was evident by ultrasound in each cycle, and an endogenous LH surge occurred. The preovulatory maximum E 2 levels were comparable to those observed in normal ovulatory women (261 Ϯ 24.7 vs. 302.6 Ϯ 10.1 pg/ mL). The serum LH level at the time of the surge in these three cycles was less than that observed in normal women, with the difference achieving statistical significance (71.8 Ϯ 5.9 vs. 117.5 Ϯ 6.2 IU/L; P Ͻ 0.05) although still within 1 sd of the normal range. FSH levels were comparable to those in normal subjects at the midcycle surge (20.3 Ϯ 2.7 vs. 23.2 Ϯ 0.9 IU/L). P 4 production by the corpus luteum was markedly reduced, as assessed by the maximum value and the integrated luteal phase P 4 level (5.1 Ϯ 2.9 vs. 23.2 Ϯ 0.7 ng/mL; P Ͻ 0.05; P 4 sum , 29.3 vs. 134.6; P Ͻ 0.05). The dose of GnRH was then increased to 250 ng/kg, and eight more cycles were performed (Fig. 4C) . The emergence of a single dominant follicle was evident, and an endogenous midcycle surge occurred in all cycles. Preovulatory peak E 2 levels were comparable to those in normal women (329.6 Ϯ 16.7 vs. 302.6 Ϯ 10.1 pg/mL). Mean LH levels at the time of the midcycle surge were below the mean observed in normal women (70.6 Ϯ 11.1 vs. 117.5 Ϯ 6.2 IU/L; P Ͻ 0.05), but within 1 sd of the normal range. FSH levels were almost identical to normal at the midcycle surge (23.3 Ϯ 4.0 vs. 23.2 Ϯ 0.9 IU/L). Most notably, compared to the cycles performed at 100 ng/ kg, the midluteal peak P 4 level for the eight cycles performed at 250 ng/kg was not different from that observed in normal women (19.9 Ϯ 2.0 vs. 23.2 Ϯ 0.8 ng/mL). The integrated P 4 value in the nonconception cycles was comparable to that seen in normal women (114.7 vs. 134.6) and significantly different from that in the cycles at 100 ng/kg (114.7 vs. 29.3; P Ͻ 0.05).
Response to pulsatile GnRH: FAS
The FAS response of the proband to pulsatile GnRH therapy was compared to those in 11 patients with IHH and 109 normal ovulatory women (Fig. 5) . A marked increase in FAS above the normal range was seen in patients with IHH in response to pulsatile GnRH (14) . This exaggerated FAS response was not apparent in the proband at either the 75 or 250 ng/kg dose.
Discussion
This report is the first to demonstrate the successful use of pulsatile GnRH to induce ovulation in a female patient with congenital HH secondary to a compound heterozygous GnRH receptor mutation. In contrast to prior statements that patients with GnRH receptor mutations should not be treated with exogenous GnRH, the proband in the current study not only developed a single dominant follicle in response to pulsatile GnRH, she also conceived three times with this therapy. Her serially increasing GnRH replacement regimen clearly illustrates the variable sensitivities of different phases of the menstrual cycle to GnRH dosage. Finally, her failure to demonstrate an exaggerated FAS response to GnRH therapy is distinct from that of other patients with congenital GnRH deficiency (14, 20) .
The mutations in the GnRH receptor of the proband are identical to those first reported in a man and his sister with incomplete HH (3). The Gln 106 Arg substitution in the first extracellular loop decreases hormone binding, and the Arg 262 Gln mutation (third intracellular loop) impairs signal transduction (3). As these represent partial loss of function mutations, we hypothesized that high dose pulsatile GnRH replacement could overcome these receptor defects. Although all patients with GnRH receptor mutations could be treated with exogenous gonadotropins, this therapeutic modality harbors the risk of hyperstimulation and multiple gestation. The use of pulsatile GnRH in properly selected patients with GnRH receptor mutations represents a safer and more physiological fertility option than exogenous gonadotropins, as has been demonstrated in other models of HH (21, 22) .
Previous studies have demonstrated that a GnRH dose of 25 ng/kg is sufficient to restore normal pituitary and gonadal function in men with HH (23, 24) . However, in women with hypothalamic amenorrhea, 25 ng/kg appears to represent a threshold dose for folliculogenesis, with successful ovulation occurring only 80% of the time (25) . Conversely, a dose of 100 ng/kg can cause higher than normal follicular phase FSH levels, elevated preovulatory E 2 levels, multiple folliculogenesis, and high early luteal phase P 4 levels (25) . Notably, however, a GnRH dose of 75 ng/kg results in follicular and luteal phase dynamics indistinguishable from normal and an overall rate of ovulation 95% higher than that seen with 25 ng/kg (8) . Therefore, 75 ng/kg was chosen as the initial starting dose for this index patient. However, as seen in the first ovulation induction cycle, this dose effected a negligible gonadotropin response and was subsequently increased to 100 ng/kg. At this higher dose, follicular phase FSH levels were within the normal range, yielding a single dominant follicle. An endogenous midcycle LH surge was present, although the LH peaks were significantly blunted compared with those observed in normal women.
Despite successful follicle recruitment, however, the luteal phases of the ovulation induction cycles performed at 100 ng/kg were inadequate, with a shortfall in serum P 4 levels compared to those in normal ovulatory women. Findings similar to those observed in this patient were seen in the 80% of hypothalamic amenorrhea patients who responded to the threshold dose of 25 ng/kg, iv, pulsatile GnRH, i.e. luteal phase P 4 production was significantly reduced (25) . During the mid-and late luteal phases, P 4 secretion correlates with LH pulsatile release (16) and is quite sensitive to LH dosage. Studies using a GnRH antagonist indicate the importance of gonadotropins (26) and in particular LH (27) in the maintenance of the corpus luteum. Despite successful folliculogenesis in our patient, no conceptions occurred during the 100 ng/kg cycles, perhaps due to this luteal phase abnormality.
During the subsequent pulsatile GnRH cycles at 250 ng/ kg, the gonadotropin and sex steroid dynamics of the proband recapitulated those of normal ovulatory women. Although previous reports have demonstrated that doses within this range in women with hypothalamic amenorrhea can cause mild ovarian hyperstimulation, elevated E 2 and P 4 responses, and multiple gestation (28) , this patient developed a single dominant follicle in each cycle and conceived three times. These data clearly indicate that the dose of GnRH of 100 ng/kg was adequate for folliculogenesis in the setting of a partially functioning GnRH receptor, but a higher dose of 250 ng/kg was necessary for fully normal luteal function. Hence, this experience once again demonstrates the critical sensitivity of the corpus luteum to GnRH-induced gonadotropin secretion.
Both men and women with HH demonstrate excessive secretion of FAS during physiological replacement with exogenous pulsatile GnRH (14, 20) . In men, this response is seen as early as 3 days after initiation of pulsatile GnRH and continues despite the achievement of normal levels of gonadotropins, testosterone, and testicular growth (20) . In women, this rise in FAS also begins early in GnRH treatment, but is further dependent on cycle stage, with the greatest increments observed in the early follicular phase (14) . The cause of this exaggerated FAS response is not clear. In studies using long acting GnRH agonists, LH levels fall, but circulating levels of FAS paradoxically increase (29 -31) . Such desensitization appears unlikely to be the predominant mechanism of the excessive secretion of FAS observed during GnRH replacement in HH patients, as supraphysiological FAS levels can be observed with GnRH doses as low as 5-10 ng/kg (20) , and desensitization of FAS in response to increasing frequencies of pulsatile GnRH has been demonstrated in subjects with HH (32) . Our group has hypothesized that as yet unrecognized factors may independently modulate FAS secretion and that this defective FAS-suppressing factor in HH subjects is unmasked in the setting of exogenous GnRH replacement (20) . In this report, the proband's FAS levels failed to rise above the normal range at GnRH doses of 75 and 250 ng/kg, suggesting that abnormal regulation of FAS in response to GnRH is not a feature of HH secondary to GnRH receptor mutations.
As the number of patients identified with GnRH receptor mutations grows, it is important to compare clinical and biochemical phenotypes in patients (both within and across families) as well as to correlate these observations with genotypes. Recent reports have described variable degrees of hypogonadism within an affected kindred containing GnRH receptor defects. In one report, a male proband (one allele, Arg 262 Gln; other allele, Gln 106 Arg and Ser 217 Arg) with complete HH demonstrated an absence of responses to single bolus GnRH, a GnRH agonist, and pulsatile GnRH administered at a dose of 20 g/pulse (263 ng/kg) every 120 min, sc (6) . In contrast, his sisters, bearing the same mutation, had normal breast development and a positive response to single injections of GnRH. One sister had detectable pulses in response to pulsatile GnRH administered at a dose of 20 g/ pulse (286 ng/kg) every 90 min, sc. In a second report, two affected males with GnRH receptor mutations (Ala 129 Asp, Arg 262 Gln) demonstrated spontaneous LH pulsatile activity, but their affected sister demonstrated no endogenous LH secretion (7) . Moreover, responses to pulsatile GnRH varied between family members.
The patient reported here adds to the variety of biochemical responses to GnRH that patients with GnRH receptor mutations may demonstrate. As noted, our proband had an identical mutation to that of the sister of the proband from the first GnRH receptor case report (3) , but lacked the spontaneous thelarche described in that paper. Therefore, it is certainly possible that other genes, in addition to the GnRH receptor, may modify receptor function or gonadotropin responsivity.
Although very valuable, some caution should be exercised regarding the interpretation of biochemical testing in these patients. First, the use of pulsatile GnRH in previous reports has been very brief (10 days or less) and has utilized a variety of doses and frequency regimens (6, 7) . Second, some studies have used different doses of GnRH on affected family members within a kindred, making comparisons in responsiveness difficult (7) . Third, the clinical usefulness of single bolus GnRH tests has been debated in the office setting (33) , and the role of such testing in patients with GnRH receptor mutations is even more uncertain. Fourth, different pulse analysis programs have been employed in the literature to assess endogenous LH and FAS secretory patterns. Criteria for what constitutes a pulse differ in different detection algorithms, which may be particularly relevant in the setting of the low amplitude pulses described in these patients.
Unfortunately, despite five successful conceptions (three during pulsatile GnRH and two during exogenous gonadotropins), this patient suffered recurrent pregnancy loss. RT-competitive PCR has recently revealed both GnRH and GnRH receptor messenger ribonucleic acid in human endometrial stromal and epithelial cells throughout all phases of the menstrual cycle, suggesting a role for GnRH in the support of early implantation (34) . Moreover, GnRH and GnRH receptor messenger ribonucleic acid expression have been identified in human preimplantation embryos, suggesting a role for GnRH in both embryonic development and implantation (35) . As the patient's sister, carrying the same GnRH receptor mutation, conceived successfully and carried two pregnancies to term, it is not clear what role, if any, the GnRH receptor mutation had in the early pregnancy losses suffered by the index case. However, as the experience with the full spectrum of the GnRH receptor mutations grows, it will be interesting to determine whether the phenotype of recurrent miscarriage is part of the spectrum of this disorder.
In summary, this report extends the biochemical phenotype of patients carrying GnRH receptor mutations. The proband demonstrates that pulsatile GnRH therapy is a safe and effective therapeutic option for some patients with HH and GnRH receptor mutations. Her data suggest that the luteal, as opposed to the follicular, phase of the menstrual cycle requires higher doses of GnRH for normal function.
